A subtle but important take out from this QR. I would caution anyone from assuming Viraleze and VivaGel sales have gone up by $669k.
In July QR: Total customer receipts of$1.0 million in the quarter included sales of Viraleze™ and VivaGel® BV and R&D service fees.
In Apr QR: Total customer receipts of$0.4 million in the quarter included sales of Viraleze™ and VivaGel® BV.
Starpharma did not disclose how much the service fees were (no itemised revenue disclosed), where the fees were from (Medicxi alone or including others), and importantly if the fees were recurring or one off/front loaded.
Will have to wait for the next QR to get a comparison however I note that generally the July QR’s (EOFY) mention some type of revenue from service fees.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-13
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $140 | 1.333K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 130016 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 173719 | 5 |
View Market Depth
| Last trade - 10.08am 12/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |